Sesen Bio, Inc.
(NASDAQ : EBIO)

( )
EBIO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.91%195.591.2%$518.97m
GILDGilead Sciences, Inc.
-1.10%72.780.9%$459.77m
BIIBBiogen Inc.
-0.76%328.411.3%$384.66m
CELGCelgene Corporation
-0.91%81.831.2%$339.18m
ILMNIllumina, Inc.
-2.57%313.413.5%$297.65m
REGNRegeneron Pharmaceuticals, Inc.
-1.72%377.552.6%$228.49m
ALXNAlexion Pharmaceuticals, Inc.
-0.37%121.492.0%$215.08m
VRTXVertex Pharmaceuticals Incorporated
-2.02%177.651.9%$210.48m
SRPTSarepta Therapeutics, Inc.
0.64%131.3416.4%$171.12m
AAgilent Technologies, Inc.
-0.92%65.631.5%$157.48m
BMRNBioMarin Pharmaceutical Inc.
-0.06%99.454.4%$135.37m
LGNDLigand Pharmaceuticals Incorporated
-1.24%200.0723.3%$115.36m
VKTXViking Therapeutics, Inc.
-1.80%14.200.9%$112.03m
NKTRNektar Therapeutics
0.35%49.085.6%$109.05m
EXASExact Sciences Corporation
-2.16%65.7725.3%$103.02m

Company Profile

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.